S&P 500
(-1.46%) 5 123.41 points
Dow Jones
(-1.24%) 37 983 points
Nasdaq
(-1.62%) 16 175 points
Oil
(0.51%) $85.45
Gas
(0.51%) $1.773
Gold
(-0.53%) $2 360.20
Silver
(-0.99%) $27.97
Platinum
(0.18%) $989.80
USD/EUR
(0.79%) $0.939
USD/NOK
(0.59%) $10.89
USD/GBP
(0.83%) $0.803
USD/RUB
(0.01%) $93.28

Realtime updates for Halozyme Therapeutics Inc [HALO]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
75.68%
return 17.93%
SELL
45.95%
return -0.34%

Live Chart Being Loaded With Signals

Commentary ():
Our systems believe the stock currently is undervalued by 0.87% compare to its pairs and should correct upwards.

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally...

Stats
Today's Volume 0
Average Volume 0
Market Cap 0
EPS $0 ( 2024-02-20 )
Next earnings date ( $0.690 ) 2024-05-14
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E 0
ATR14 $0 (0.00%)
Insider Trading
Date Person Action Amount type
2024-03-26 Labarre Michael J. Buy 2 890 Common Stock
2024-03-26 Labarre Michael J. Buy 292 Common Stock
2024-03-26 Labarre Michael J. Buy 8 436 Common Stock
2024-03-26 Labarre Michael J. Sell 2 890 Option to Purchase Common Stock
2024-03-26 Labarre Michael J. Sell 8 436 Option to Purchase Common Stock
INSIDER POWER
18.40
Last 100 transactions
Buy: 622 606 | Sell: 439 990
Correlation (AI algo v.1.1b): Undervalued: 0.87% $40.48 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Halozyme Therapeutics Inc Correlation

10 Most Positive Correlations
LWAC0.957
SRAC0.91
NETE0.889
AMRB0.889
ACER0.853
HOUR0.849
KNSA0.839
MMAC0.831
EEIQ0.829
WBA0.829
10 Most Negative Correlations
TLGT-0.945
SVAC-0.942
GOODM-0.919
SIBN-0.88
RPHM-0.88
PAIC-0.872
SNPO-0.86
MTSL-0.85
PYXS-0.845
XOG-0.843

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Halozyme Therapeutics Inc Financials

Annual 2023
Revenue: $829.25M
Gross Profit: $636.89M (76.80 %)
EPS: $2.13
Q4 2023
Revenue: $230.04M
Gross Profit: $177.74M (77.27 %)
EPS: $0.660
Q3 2023
Revenue: $216.03M
Gross Profit: $161.21M (74.62 %)
EPS: $0.620
Q2 2023
Revenue: $221.04M
Gross Profit: $170.97M (77.35 %)
EPS: $0.570

Financial Reports:

No articles found.

Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators